A multicenter, prospective, randomized, double‐blind, placebo‐controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma
Rachel K. Hoyles, R Ellis, Jessica Wellsbury et al. · Arthritis & Rheumatism · 2006
OBJECTIVE: The lack of randomized controlled trials (RCTs) in pulmonary fibrosis in systemic sclerosis (SSc) has hampered an evidence-based approach to treatment. This RCT was undertaken to investigate the effects of intravenous (IV) cyclophosphamide (CYC) followed by azathioprine (AZA) treatment in pulmonary fibrosis in SSc. METHODS: Forty-five patients were randomized to receive low-dose prednisolone and 6 infusions (monthly) of CYC followed by oral AZA, or placebo. Primary outcome measures were change in percent predicted forced vital capacity (FVC) and change in single-breath diffusing capacity for carbon monoxide (DLCO). Secondary outcome measures included changes in appearance on high-resolution computed tomography and dyspnea scores. An intent-to-treat statistical analysis was performed. RESULTS: At baseline, there were no significant group differences in factors linked to outcome, including severity of pulmonary fibrosis and autoantibody status. Sixty-two percent of the patients completed the first year of treatment. Withdrawals included 9 patients (6 from the placebo group) with significant decline in lung function, 2 with treatment side effects (both from the active treatment group), and 6 with non-trial-related comorbidity. No hemorrhagic cystitis or bone marrow suppression was observed. Estimation of the relative treatment effect (active treatment versus placebo) adjusted for baseline FVC and treatment center revealed a favorable outcome for FVC of 4.19%; this between-group difference showed a trend toward statistical significance (P = 0.08). No improvements in DLCO or secondary outcome measures were identified. CONCLUSION: This trial did not demonstrate significant improvement in the primary or secondary end points in the active treatment group versus the group receiving placebo. However, for FVC there was a trend toward statistical significance between the 2 groups. This suggests that treatment of pulmonary fibrosis in SSc with low-dose prednisolone and IV CYC followed by AZA stabilizes lung function in a subset of patients with the disease. Therapy was well tolerated with no increase in serious adverse events.
Cited by 739 works. doi:10.1002/art.22204
Authors
- Rachel K. Hoyles
- R Ellis
- Jessica Wellsbury
- Belinda Lees
- Pauline Newlands
- Nicole S L Goh
- Christopher T. Roberts
- Sujal R. Desai
- Ariane L. Herrick
- Neil John McHugh
- Noeleen M. Foley
- Stanley B. Pearson
- Paul E. Emery
- Douglas James Veale
- Christopher P. Denton
- Athol Umfrey Wells
- Carol M. Black
- Roland M. du Bois
References
- Preliminary criteria for the classification of systemic sclerosis (scleroderma)
- Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
- Cyclophosphamide versus Placebo in Scleroderma Lung Disease
- Azathioprine Combined with Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: A Prospective Double-blind, Randomized, Placebo-controlled Clinical Trial
- Guidelines for the measurement of respiratory function
- Analyses of Efficacy End Points in a Controlled Trial of Interferon-γ1b for Idiopathic Pulmonary Fibrosis
- Fibrosing Alveolitis Associated with Systemic Sclerosis Has a Better Prognosis Than Lone Cryptogenic Fibrosing Alveolitis
- Physiology Is a Stronger Predictor of Survival than Pathology in Fibrotic Interstitial Pneumonia
- Cyclophosphamide Is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and Alveolitis
- CT Features of Lung Disease in Patients with Systemic Sclerosis: Comparison with Idiopathic Pulmonary Fibrosis and Nonspecific Interstitial Pneumonia